GalNAc-LNP Development

Price Inquiry

Targeted Hepatic RNA DeliveryIntegrated GalNAc-Lipid Nanoparticle DevelopmentAdvanced GalNAc-LNP Solutions for Liver-Directed Therapeutics

Accelerate liver-targeted RNA programs with GalNAc-lipid nanoparticle development services built for biotechnology innovators, pharmaceutical developers, translational research groups, and CDMO outsourcing teams. Our platform combines ligand engineering, ionizable lipid formulation, microfluidic process development, and analytical characterization to support GalNAc-LNP systems for siRNA, mRNA, and selected oligonucleotide payloads. By integrating GalNAc-mediated hepatocyte recognition with the intracellular delivery strengths of lipid nanoparticles, we help clients address one of the most important challenges in nucleic acid therapeutics: achieving efficient liver uptake while maintaining manufacturability, payload integrity, and acceptable safety margins.

From early feasibility studies to process transfer support, we design GalNAc-LNP delivery systems around real development priorities: ASGPR-mediated targeting, controlled particle size, robust encapsulation efficiency, low polydispersity, serum stability, and scalable manufacturing logic. Whether your team is advancing a discovery-stage siRNA candidate, optimizing an mRNA formulation for hepatic expression, or evaluating targeted alternatives to conventional LNPs or GalNAc-siRNA conjugation, we provide technically grounded development workflows aligned with modern RNA therapeutic programs.

What Are GalNAc Lipid Nanoparticles?

GalNAc lipid nanoparticles are liver-targeted RNA delivery systems that combine the endosomal escape and payload protection advantages of LNPs with N-acetylgalactosamine ligand-mediated uptake through the asialoglycoprotein receptor (ASGPR) on hepatocytes. Compared with conventional LNPs, GalNAc-LNP platforms can improve hepatic selectivity and reduce dependence on passive biodistribution alone. Compared with GalNAc-only conjugates, they can offer broader payload compatibility, higher encapsulation capacity, and greater formulation flexibility for complex RNA modalities. Our service focuses on rational design, formulation screening, ligand incorporation, and analytical assessment to build developable GalNAc-LNP candidates for liver-targeted drug delivery.

GalNAc lipid nanoparticle delivery system targeting hepatocytes via ASGPR for liver-specific RNA therapeutics

Schematic representation of GalNAc-functionalized lipid nanoparticles enabling ASGPR-mediated hepatocyte uptake and efficient delivery of siRNA and mRNA for liver-targeted gene regulation

Key Development Challenges We Address

Limited Hepatocyte Selectivity

We optimize ligand density, GalNAc presentation, and surface architecture to improve ASGPR-mediated uptake and enhance liver-targeted delivery beyond non-targeted LNP behavior.

Suboptimal RNA Encapsulation

Our formulation studies tune N/P ratio, mixing conditions, buffer systems, and lipid composition to improve encapsulation efficiency for siRNA, mRNA, and other oligonucleotide payloads.

Endosomal Escape Constraints

We evaluate ionizable lipids, helper lipids, and structural parameters that influence intracellular release, helping programs balance uptake with productive cytosolic delivery.

Toxicity and Tolerability Risk

Our development approach considers charge behavior, excipient burden, residual solvents, and dose-enabling formulation design to reduce avoidable safety liabilities during scale-up.

Poor Reproducibility at Scale

We build scalable workflows using controlled mixing, in-process monitoring, and critical quality attribute tracking so promising discovery formulations can transition toward CMC readiness.

Incomplete Characterization Packages

We generate decision-useful analytical data covering particle size, PDI, zeta potential, ligand incorporation, RNA integrity, release behavior, and formulation stability.

GalNAc-LNP Formulation and Delivery Services

We offer a structured service portfolio for GalNAc-LNP delivery systems, spanning ligand chemistry, RNA formulation, characterization, process optimization, and scale-up support. Each project is designed around the practical needs of RNA therapeutic development: liver specificity, payload stability, manufacturability, and clear go/no-go data for preclinical progression.

GalNAc Ligand Engineering for LNP Targeting

Capabilities include:

Design of GalNAc-bearing lipids and surface-display strategies for hepatocyte targeting
Evaluation of spacer length, valency, and ligand accessibility for ASGPR engagement
Support for pre-inserted and post-inserted GalNAc architectures
Development of ligand formats compatible with siRNA and mRNA LNP platforms
Assessment of ligand density versus colloidal stability and payload retention
Comparative screening against non-targeted controls and ligand-free benchmarks
Surface chemistry strategies aligned with scalable formulation workflows
Technical alignment with programs exploring GalNAc-only conjugates and hybrid delivery formats
Stability-oriented design to minimize premature ligand loss during storage
Data packages supporting platform selection for liver-targeted RNA therapeutics

Typical focus:

Ligand density, spacer chemistry, ASGPR uptake, hepatic selectivity

Ionizable Lipid Screening for GalNAc-LNP Systems

Capabilities include:

Screening of ionizable lipids across pKa, structure, and charge-transition profiles
Evaluation of ionizable/helper lipid balance for encapsulation and endosomal escape
Optimization of formulation windows for hepatic RNA delivery performance
Comparative assessment of potency-driving versus tolerability-driven compositions
Support for novel lipid candidates and platform benchmarking studies
Integration of cholesterol, phospholipid, and PEG-lipid variables into design space
Rapid down-selection based on particle size, PDI, and payload retention
Structure-property analysis to identify robust development leads
Formulation guidance for repeat-dose and dose-intensification strategies
Decision support for chemistry, manufacturing, and control planning

Typical focus:

pKa optimization, endosomal escape, potency-tolerability balance

siRNA Encapsulation and Silencing-Focused Formulation

Capabilities include:

Formulation development for duplex siRNA payloads targeting liver-expressed genes
Optimization of N/P ratio, acidic mixing conditions, and RNA concentration
Screening for encapsulation efficiency, particle integrity, and serum robustness
Support for chemically modified siRNA and targeted RNAi workflows
Formulation benchmarking versus cholesterol-conjugated siRNA and alternative hepatic delivery formats
Evaluation of cryoprotectants and storage conditions for formulation stability
Development of targeted GalNAc-LNP systems for potency screening and translational studies
Release and protection studies under physiologically relevant conditions
Compatibility assessment with in vitro uptake and knockdown workflows
Technical support for discovery-to-preclinical formulation refinement

Typical focus:

Encapsulation efficiency, RNA integrity, hepatocyte uptake, silencing performance

Liver-Directed mRNA LNP Development

mRNA-focused capabilities include:

Formulation development for hepatic expression, protein replacement, and gene editing support studies
Optimization of large-payload encapsulation without excessive particle growth
Evaluation of GalNAc display strategies compatible with mRNA-loaded LNP systems
Screening of excipient systems for payload integrity during mixing and storage
Assessment of translation-enabling delivery conditions in hepatocyte-relevant models
Design support for balancing targeting, circulation behavior, and intracellular release
Comparative studies between conventional LNP and GalNAc-LNP architectures
Stability-oriented buffer and cryopreservation strategy development
Analytical workflows for encapsulation, particle size, and RNA quality confirmation

Typical focus:

mRNA integrity, hepatic expression, particle uniformity, storage robustness

Oligonucleotide-Loaded Lipid Nanoparticle Development

Capabilities include:

Formulation support for antisense oligonucleotides, splice-switching oligos, and related payloads
Assessment of oligonucleotide chemistry effects on encapsulation and release
Screening of GalNAc-functionalized surface designs for hepatocyte-directed delivery
Integration of formulation logic for ASO programs complementary to GalNAc-ASO conjugation
Optimization of ionic strength, buffer pH, and particle formation conditions
Characterization of loading, leakage, and nuclease protection behavior
Support for discovery screening and preclinical candidate evaluation
Custom formulation studies for mixed or dual-oligonucleotide payload concepts
Analytical methods matched to modified oligonucleotide backbones
Development of data packages for platform feasibility decisions

Typical focus:

ASO loading, leakage control, hybrid platform assessment

Microfluidic Process Development and Scale Translation

Capabilities include:

Development of controlled-mixing processes for reproducible GalNAc-LNP manufacture
Flow-rate ratio and total-flow screening for particle size and PDI control
Translation of benchtop formulations toward pilot-relevant process conditions
Process parameter mapping to define robust operating windows
Evaluation of solvent removal, diafiltration, and concentration workflows
In-process sampling strategies for critical quality attribute monitoring
Support for technology transfer packages and scale-up risk reduction
Raw material and process logic compatible with regulated manufacturing pathways
Comparative review of batch versus continuous processing considerations
Documentation support for development history and process rationale

Typical focus:

Mixing reproducibility, CQA control, scale-up feasibility

PEG-Lipid and Helper Lipid Optimization

Capabilities include:

Selection of PEG-lipid content to balance colloidal stability with receptor accessibility
Optimization of cholesterol and phospholipid fractions for membrane behavior and particle integrity
Assessment of PEG shedding logic where relevant to targeted hepatic uptake
Support for alternative stealth strategies where standard PEG levels impede targeting
Evaluation of helper lipid effects on encapsulation and intracellular release
Tuning of surface composition to reduce aggregation during storage and handling
Formulation comparison studies across delivery routes and dosing concepts
Compatibility assessment with GalNAc-bearing lipids and surface ligands
Development of composition ranges suitable for robust manufacturing
Guidance on excipient trade-offs relevant to translational development

Typical focus:

Surface shielding, ligand accessibility, colloidal stability

Click Chemistry and Ligand Conjugation Support

Capabilities include:

Ligand-to-lipid and linker installation strategies for GalNAc-functionalized excipients
Use of orthogonal conjugation routes to preserve ligand integrity and formulation compatibility
Evaluation of amide, thiol, and bioorthogonal coupling methods for lipid modification
Support for linker chemistry selection based on stability and surface exposure requirements
Development workflows compatible with discovery and preclinical material generation
Design of modular chemistries for rapid library synthesis and screening
Process considerations for purification of modified lipids prior to formulation
Analytical confirmation of conjugation efficiency and product identity
Integration with lipid nanoparticle formulation and downstream characterization
Technical support for clients developing customized targeted RNA delivery platforms

Typical focus:

Ligand-to-lipid conjugation, linker selection, orthogonal chemistry

Analytical Characterization of GalNAc-LNP CQAs

Capabilities include:

Particle size, PDI, and zeta potential analysis for formulation screening and release readiness
Quantification of encapsulation efficiency and free RNA content using orthogonal methods
Assessment of ligand incorporation and surface presentation consistency
RNA integrity analysis before and after formulation processing
Morphology assessment using electron microscopy when required
Stability studies under refrigerated, frozen, and stress-storage conditions
Evaluation of serum stability and release behavior in biologically relevant media
Method development support for custom payloads and modified oligonucleotides
Data trending to identify formulation drift during process optimization
Reporting packages suitable for decision-making across discovery, preclinical, and CMC teams

Typical focus:

CQA definition, orthogonal testing, lot-to-lot comparability

Lipid Conjugation and Surface Modification Support

Capabilities include:

Custom synthesis and modification of lipid-linked ligands for targeted LNP systems
Support for GalNAc-bearing lipid variants, helper-lipid analogs, and linker exploration
Development of functionalized lipids compatible with microfluidic formulation workflows
Optimization of conjugation routes to preserve amphiphile behavior and formulation performance
Purification and identity confirmation of modified lipid intermediates
Surface modification support for next-generation targeted nanoparticle platforms
Comparative studies of covalent incorporation versus post-formulation insertion
Technical evaluation of ligand stability during manufacturing and storage
Formulation-ready material preparation for discovery and preclinical studies
Integration with targeted delivery platform design and analytical characterization

Typical focus:

Modified lipids, formulation compatibility, surface engineering

Platform Comparison for Liver-Targeted RNA Delivery

Selecting the right liver-targeted RNA delivery platform depends on payload class, dosing strategy, target biology, and manufacturing requirements. The table below summarizes common strategic differences between conventional LNPs, GalNAc conjugates, and GalNAc-LNP delivery systems to support early platform selection and development planning.

Platform	Liver Targeting Mechanism	Payload Compatibility	Typical Strengths	Development Considerations
Conventional LNP	Passive biodistribution with liver exposure influenced by particle composition and serum interactions	siRNA, mRNA, some oligonucleotides	Strong intracellular delivery capability and established formulation workflows	Limited cell-specific targeting and potential off-target uptake outside hepatocytes
GalNAc Conjugate	Direct ASGPR recognition through covalently attached GalNAc ligand	Primarily siRNA and ASO formats	Efficient hepatocyte targeting with relatively defined molecular architecture	Lower payload flexibility and less suitable for larger RNA constructs such as mRNA
GalNAc-LNP	ASGPR-mediated hepatocyte recognition combined with nanoparticle-driven intracellular delivery	siRNA, mRNA, selected ASO and oligonucleotide payloads	Hybrid advantage of active liver targeting, payload protection, and formulation tunability	Requires careful control of ligand density, particle attributes, and scale-up reproducibility
Targeted Liposome	Ligand-mediated surface recognition on liposomal carrier	Nucleic acids and small molecules depending on composition	Flexible surface engineering and broad conjugation options	Often less efficient for endosomal escape than optimized ionizable LNP systems
Antibody-Conjugated LNP	Receptor targeting through antibody or fragment on particle surface	Broad payload compatibility	Useful for extrahepatic or cell-specific targeting concepts	More complex manufacturing and steric constraints compared with GalNAc-mediated liver targeting
Cholesterol-Conjugated RNA	Lipophilic association and hepatic exposure driven by transport pathways	Mainly siRNA and oligonucleotides	Simpler molecular format for selected delivery use cases	Lower formulation flexibility and less control over intracellular delivery than GalNAc-LNP systems
Hybrid Ligand-LNP Platform	Combination of GalNAc or other ligands with optimized nanoparticle composition	Modality-dependent; can be tailored to multi-program pipelines	Allows platform customization around tissue access, potency, and manufacturability	Requires rigorous structure-function characterization and comparability controls
Non-Targeted Oligonucleotide LNP	No active ligand; performance driven mainly by physicochemical properties	Oligonucleotides and selected RNA payloads	Faster early screening and simpler composition benchmarking	Reduced hepatic precision compared with GalNAc-decorated platforms
Ligand-Functionalized Nanoparticle	Receptor-specific uptake based on selected surface ligand	Depends on nanoparticle core and cargo type	Broad design space for targeted delivery research	Targeting success depends on receptor biology, ligand orientation, and particle stability
ASGPR-Focused RNA Delivery Platform	Designed specifically around hepatocyte receptor-mediated uptake pathways	Best suited to liver-relevant oligonucleotide and RNA programs	Strong strategic fit for liver-directed drug discovery pipelines	Needs integrated chemistry, formulation, analytics, and translational evaluation
Discovery-Stage Screening LNP	Varies by screening design	Early research RNA payloads	Rapid iteration and composition ranking during lead optimization	Findings must be translated carefully into scalable, controlled formulations
Preclinical Candidate Formulation	Optimized targeted or non-targeted mechanism defined by program objectives	Candidate-specific	Balanced toward reproducibility, analytical depth, and development continuity	Requires tighter control of raw materials, CQAs, and process consistency
Translational GalNAc-LNP	ASGPR-targeted uptake with scalable ionizable nanoparticle design	siRNA, mRNA, selected oligonucleotide payloads	Strong fit for liver-targeted RNA delivery programs needing both targeting and delivery efficiency	Success depends on integrated formulation science, characterization, and manufacturing strategy
Exploratory Combination Platform	Mixed targeting and carrier approaches selected for hypothesis-driven studies	Flexible	Useful for mechanism studies and platform innovation	May require more extensive comparability work before development standardization
Partner-Ready Development Package	Mechanism aligned with selected commercial development path	Candidate-specific	Facilitates outsourcing, tech transfer, and program advancement decisions	Requires well-documented formulation rationale and analytical evidence

Design Parameters and Conjugation Strategies for GalNAc-LNP Development

High-performing GalNAc-LNP systems depend on more than one variable. Ligand chemistry, ionizable lipid behavior, helper-lipid composition, surface shielding, and process conditions all influence liver targeting, RNA protection, and intracellular delivery. We use formulation science and bioconjugation logic together to define robust design space for targeted RNA delivery platforms.

Design Element	Technical Focus	Common Development Use	Impact on GalNAc-LNP Performance
GalNAc-Lipid Conjugation	Attachment of GalNAc to lipid anchors through stable linkers with controlled spacer architecture	Liver-targeted LNP design, ASGPR-focused screening	Influences receptor recognition, surface accessibility, and ligand retention during formulation and storage
Maleimide-Based Linker Installation	Thiol-reactive chemistry used for selective linker attachment and modular lipid functionalization	Ligand-lipid synthesis, targeted nanoparticle modification	Supports controlled conjugation when thiol-containing intermediates are part of the lipid design route
Bioorthogonal Click Chemistry	Orthogonal coupling approach for installing GalNAc motifs or other functional ligands under mild conditions	Ligand library synthesis, modular surface engineering	Enables efficient coupling while helping preserve sensitive functional groups and formulation compatibility
Ionizable Lipid Selection	Screening of lipid structure and pKa behavior to support RNA complexation and endosomal release	siRNA and mRNA LNP optimization	Directly affects encapsulation, intracellular delivery efficiency, and tolerability profile
PEG-Lipid Tuning	Adjustment of PEG-lipid identity and level to balance colloidal stability with receptor engagement	Targeted LNP refinement, stability optimization	Can improve storage stability but excessive shielding may reduce GalNAc accessibility
Helper Lipid Optimization	Cholesterol and phospholipid selection to tune membrane packing, particle formation, and release behavior	Core composition screening across RNA payload types	Influences nanoparticle integrity, serum behavior, and intracellular trafficking outcomes
Microfluidic Mixing Control	Control of flow-rate ratio, total flow, and solvent conditions during nanoparticle assembly	Scalable process development and comparability studies	Strongly affects particle size, PDI, reproducibility, and downstream process robustness
RNA-to-Lipid Ratio Optimization	Adjustment of N/P ratio and formulation concentration based on payload chemistry and target quality profile	Encapsulation optimization for siRNA, mRNA, and ASO	Determines loading efficiency, free RNA fraction, and particle stability
Post-Insertion Strategy	Addition of GalNAc-bearing components after core LNP formation when formulation logic requires surface adaptation	Late-stage targeting modification and flexibility studies	Offers modularity but requires confirmation of ligand insertion efficiency and stability
Buffer and Cryoprotectant Selection	Optimization of aqueous environment to protect particle integrity and RNA stability during storage	Refrigerated and frozen formulation development	Improves shelf stability, freeze-thaw tolerance, and batch handling consistency

Analytical Methods and Data Package for GalNAc-LNP Programs

We provide a characterization package designed for formulation scientists, translational teams, and CMC stakeholders. The goal is not just to generate data, but to provide development-relevant interpretation of critical quality attributes for GalNAc-LNP delivery systems.

Analytical Item	Description / Method	Delivered Data
Particle Size and PDI	DLS and orthogonal particle sizing where appropriate	Mean size, distribution profile, PDI trend data
Encapsulation Efficiency	Fluorescence-based or chromatographic free-RNA discrimination methods	% encapsulation, free payload fraction
RNA Integrity Verification	Gel-based, electrophoretic, or LC-supported integrity assessment	Integrity profile, degradation assessment
Surface Charge	Zeta potential measurement under defined buffer conditions	Surface charge report, formulation comparison data
GalNAc Incorporation Assessment	Ligand-specific analytical verification and relative incorporation analysis	Ligand incorporation summary, batch comparability insight
Morphology Evaluation	TEM or cryo-relevant imaging support when required	Morphology images, structural observations
Stability Assessment	Refrigerated, frozen, and stress-condition monitoring	Time-course stability results, storage recommendations

Typical Workflow for GalNAc-LNP Delivery System Development

Program Assessment and TPP Alignment

We review payload class, target biology, route assumptions, and development stage to define a practical target product profile for the GalNAc-LNP program.

Ligand and Lipid Design Strategy

GalNAc architecture, ionizable lipid options, helper lipids, and PEG-lipid levels are selected based on hepatocyte targeting goals, payload behavior, and manufacturability.

Formulation Screening and Assembly

Candidate compositions are prepared using controlled mixing workflows to optimize particle size, PDI, loading efficiency, and surface display of the GalNAc ligand.

Purification and Post-Processing

Solvent removal, buffer exchange, concentration, and stabilization steps are configured to protect RNA quality while maintaining nanoparticle integrity and target performance.

Characterization and Performance Review

We generate analytical and biological data on CQAs including size, PDI, zeta potential, encapsulation efficiency, ligand incorporation, stability, and uptake behavior.

Reporting, Optimization, and Next-Step Planning

Clients receive a structured development summary with technical interpretation, optimization recommendations, and support for preclinical transition, tech transfer, or expanded formulation studies.

Why Partner With Us for GalNAc-LNP Development

Integrated Delivery and Conjugation Expertise

Our team works at the intersection of bioconjugation chemistry and nanoparticle formulation, enabling efficient development of GalNAc-functionalized LNP systems rather than treating targeting and encapsulation as separate tasks.

Modality-Aware RNA Platform Design

We tailor development strategies to siRNA, mRNA, and selected oligonucleotide payloads, recognizing that encapsulation behavior, release requirements, and stability risks differ across therapeutic modalities.

Discovery-to-Scale Development Logic

Our formulation services are designed with scale translation in mind, helping clients avoid early choices that create unnecessary CMC challenges during process transfer or later manufacturing.

Decision-Useful Analytical Packages

We provide characterization data that supports formulation ranking, comparability assessment, and technical review across discovery, translational, and CMC stakeholders.

Rational ASGPR Targeting Optimization

Our development workflow evaluates the practical trade-offs between ligand density, shielding, uptake, and intracellular delivery so liver targeting improvements are technically meaningful rather than only conceptual.

Flexible CDMO Collaboration Model

We support single-study engagements, platform screening projects, and integrated development programs, making us a practical partner for emerging biotech teams and established pharmaceutical organizations alike.

Applications of GalNAc-LNP Delivery Platforms

siRNA Therapeutics

Enable liver-directed gene silencing programs where hepatocyte uptake and intracellular release both drive pharmacologic outcome.
Support target validation, lead optimization, and preclinical candidate formulation for RNAi pipelines.
Compare GalNAc-LNP performance with standalone conjugate formats and conventional LNP controls.
Help teams refine dosing strategy, payload loading, and development risk before scale-up.

mRNA Liver Expression Programs

Support hepatic protein expression applications such as protein replacement, secreted factor delivery, or research-stage editing workflows.
Optimize large-payload encapsulation while maintaining particle uniformity and acceptable process robustness.
Evaluate GalNAc-LNP architectures for programs requiring more hepatic precision than standard LNP systems.
Build platform knowledge for translational mRNA development and formulation selection.

ASO and Oligonucleotide Delivery

Assess GalNAc-LNP approaches for antisense and other oligonucleotide modalities where carrier-based delivery may add strategic value.
Compare formulation-driven delivery with direct conjugate strategies for liver-targeted drug development.
Support chemistry-compatible encapsulation and release studies for modified oligonucleotide payloads.
Generate data packages for platform selection across discovery and translational teams.

Liver-Targeted Drug Discovery

Provide targeted RNA delivery tools for validating hepatic targets and pathway modulation in translational research.
Support candidate ranking by linking formulation attributes with uptake and pharmacology-relevant outputs.
Enable exploration of hybrid delivery concepts where targeting and intracellular delivery must both be optimized.
Reduce development uncertainty with structured formulation and analytics support.

Platform and Library Screening

Screen GalNAc-lipid variants, ionizable lipids, helper lipids, and process parameters within a single development framework.
Build internal knowledge around structure-function relationships in targeted LNP systems.
Support rapid iteration for companies establishing proprietary RNA delivery platforms.
Create a development path from exploratory studies to candidate-focused optimization.

Targeted Nanomedicine Research

Explore GalNAc-functionalized nanoparticles within broader nanomedicine and targeted delivery programs.
Compare ligand-directed LNP behavior with liposomes, polymeric nanoparticles, and other carrier systems.
Support mechanistic studies of receptor-mediated uptake, intracellular trafficking, and release.
Generate development-relevant insights for next-generation liver-targeted delivery concepts.

What RNA Therapeutics Clients Value

"Their team understood the difference between simply decorating an LNP and building a functional GalNAc-LNP system. The formulation data helped us quickly prioritize a viable liver-targeted siRNA direction."

— Director of Delivery Sciences, US RNA Therapeutics Company

"We needed a partner who could connect ligand chemistry, particle engineering, and CMC thinking. Their workflow gave our translational team much clearer decision points for advancing the program."

— Senior CMC Lead, European Biopharmaceutical Developer

"The analytical depth was especially valuable. Instead of generic nanoparticle data, we received interpretation that helped us understand which parameters were truly driving hepatic delivery performance."

— Principal Scientist, Asia-Pacific Nucleic Acid Medicines Startup

Build a Stronger GalNAc-LNP Strategy for Liver-Targeted RNA Therapeutics

Whether you are evaluating targeted alternatives to conventional LNPs, advancing a liver-directed siRNA asset, or building a broader RNA delivery platform, our team can support the chemistry, formulation, analytics, and development planning needed to move with confidence. We work with biotech and pharmaceutical partners on focused studies as well as integrated development programs, including projects related to nanoparticles conjugation, liposome conjugation, and targeted oligonucleotide delivery. Contact us to discuss your GalNAc-LNP development goals and receive a technically aligned proposal for your liver-targeted RNA delivery program.

Frequently Asked Questions (FAQ)

How do GalNAc-LNPs improve liver-targeted drug delivery?

GalNAc-LNPs enhance liver targeting through receptor-mediated uptake. The GalNAc ligand binds specifically to ASGPR on hepatocytes, increasing cellular uptake, while the LNP structure protects RNA payloads and facilitates endosomal escape for effective gene silencing or protein expression.

What types of RNA therapeutics can be delivered using GalNAc-LNPs?

GalNAc-LNP systems are compatible with multiple RNA modalities, including siRNA, mRNA, and certain antisense oligonucleotides (ASOs). They are particularly valuable for liver-related diseases where targeted delivery improves therapeutic index and reduces systemic exposure.

What is the difference between GalNAc conjugates and GalNAc-LNPs?

GalNAc conjugates are small, chemically defined molecules where RNA is directly linked to a GalNAc ligand, typically used for siRNA or ASO delivery. In contrast, GalNAc-LNPs are nanoparticle-based systems that encapsulate RNA payloads, offering greater flexibility for larger molecules like mRNA and improved control over formulation parameters.

Why are ionizable lipids important in GalNAc-LNP formulations?

Ionizable lipids are critical for RNA encapsulation and intracellular delivery. They remain neutral at physiological pH to reduce toxicity but become positively charged in acidic endosomal environments, promoting membrane disruption and RNA release into the cytoplasm.

What are the key parameters affecting GalNAc-LNP performance?

Key parameters include particle size, polydispersity index (PDI), encapsulation efficiency, ionizable lipid pKa, GalNAc ligand density, PEG-lipid content, and RNA-to-lipid ratio. These factors collectively influence targeting efficiency, stability, and biological activity.